8-K: Microbot Medical to Lead Endovascular Robotics Discussion at Global Surgery Summit Amidst Anticipated FDA Clearance

Microbot Medical Inc. announced its participation and leadership in the inaugural Endovascular Robotics session at the Society of Robotic Surgery annual meeting, while also preparing for the U.S. launch of its LIBERTY system pending anticipated FDA 510(k) clearance this quarter.

Summary

• Microbot Medical Inc. will participate in and open the inaugural Endovascular Robotics session at the Society of Robotic Surgery (SRS) annual meeting in Strasbourg, France, from July 16-20, 2025.
• The panel session, titled 'Endovascular Robotics; the next frontier for robotic surgery,' is scheduled for Saturday, July 19, 2025, at 1:30 AM CEST.
• Harel Gadot, Microbot Medical's Chairman, CEO, and President, will present an overview of the endovascular robotic market during the session.
• The company is strengthening its sales and marketing infrastructure in preparation for the U.S. launch of its LIBERTY Endovascular Robotic System.
• Microbot Medical is awaiting an anticipated U.S. Food and Drug Administration (FDA) 510(k) decision for the LIBERTY system during the current quarter.
• The LIBERTY system is described as the world's first single-use, fully disposable endovascular robotic system, designed to eliminate traditional barriers to accessing advanced robotic systems.
• The LIBERTY system is currently an investigational device and not available for sale in the U.S. pending FDA 510(k) clearance.

Sentiment

Score: 7

Explanation: The sentiment is generally positive due to the company's prominent participation in a key industry conference, the anticipated FDA clearance within the current quarter, and the unique positioning of its LIBERTY system. However, it is tempered by the pre-commercial stage status and the inherent risks associated with regulatory approvals and the need for additional capital.

Positives

• Microbot Medical is opening the inaugural Endovascular Robotics session at a prominent global conference (Society of Robotic Surgery annual meeting), indicating industry recognition and leadership.
• Participation in the SRS meeting provides a timely platform to introduce and educate Interventional Radiologists and the broader medical community on the LIBERTY system.
• The company is actively strengthening its sales and marketing infrastructure, signaling progress towards commercialization.
• Anticipated FDA 510(k) decision for the LIBERTY system is expected during the current quarter, which could pave the way for U.S. market entry.
• The LIBERTY system is positioned as the 'world's first single-use, fully disposable endovascular robotic system,' potentially offering a unique market advantage by addressing access barriers.

Negatives

• The LIBERTY Endovascular Robotic System is still an investigational device and is not yet available for sale in the U.S., pending regulatory clearance.
• Microbot Medical is a pre-commercial stage medical technology company, indicating it has not yet generated significant revenue from product sales.
• The company's ability to continue its transition to a commercially focused entity is dependent on obtaining additional working capital.

Risks

• The company's need for and ability to obtain additional working capital to continue its transition to a commercially focused company.
• Market conditions impacting the development and commercialization of the LIBERTY Endovascular Robotic System.
• Uncertainty in the results of regulatory pathways and regulatory approvals, specifically whether the FDA will timely grant 510(k) clearance to commercially market the LIBERTY system in the United States, if at all.
• Uncertainty resulting from political, social, and geopolitical conditions, including any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S.
• Disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran, and other neighboring countries.
• Challenges in the maintenance of intellectual property rights.

Future Outlook

Microbot Medical anticipates future growth in research, technology, clinical development, commercialization, and potential opportunities for its LIBERTY Endovascular Robotic System. The company is preparing for the U.S. launch of the LIBERTY system and expects an FDA 510(k) clearance decision during the current quarter. It also foresees the need for additional working capital to support its transition to a commercially focused company.

Management Comments

• Microbot Medical applauds the Society of Robotic Surgery (SRS) for recognizing the growing need to spotlight the endovascular robotics field, which is believed to be driven by rapid innovation and rising market demand.
• Harel Gadot, Chairman, CEO, and President, will present an overview of the endovascular robotic market at the SRS meeting.

Industry Context

The announcement highlights the growing importance of robotics in endovascular procedures, a trend recognized by the Society of Robotic Surgery through its inaugural Endovascular Robotics session. Microbot Medical's participation and leadership in this session position it at the forefront of this emerging field, alongside other medical robotics companies discussing technologies in peripheral vascular, neurovascular, and cardiovascular spaces. The focus on a single-use, fully disposable system aims to address existing barriers to adoption in the broader robotic surgery market.

Stakeholder Impact

• Shareholders: Potential positive impact from increased visibility and anticipated FDA clearance, but also exposure to risks related to regulatory approval, market conditions, and the need for additional capital.
• Employees: Continued focus on strengthening sales and marketing infrastructure suggests potential for growth and new opportunities.
• Customers (Interventional Radiologists and medical community): Opportunity to be educated on the LIBERTY system, potentially leading to future adoption if cleared.
• Regulatory Authorities (FDA): The company is actively engaged in the 510(k) clearance process, awaiting a decision.

Next Steps

• Harel Gadot, Chairman, CEO, and President, will present an overview of the endovascular robotic market at the SRS annual meeting on July 19, 2025.
• Microbot Medical will continue strengthening its sales and marketing infrastructure for the LIBERTY system launch in the United States.
• The company awaits the anticipated U.S. Food and Drug Administration (FDA) 510(k) decision for the LIBERTY system during the current quarter.

Key Dates

Keywords

Endovascular Robotics, LIBERTY System, Microbot Medical, Robotic Surgery, FDA 510(k) clearance, Medical Technology, Surgical Robotics, Interventional Radiology, Neurovascular, Cardiovascular, Peripheral Vascular